炎症性肠病患者接种COVID-19疫苗有效且不增加疾病加重风险
基于以色列两个健康维护组织覆盖35%人口的IBD患者队列,12109例接种两剂BNT162b2疫苗,其中4946例与非IBD对照匹配后两组COVID-19发生率均为0.3%(OR=1,95%CI 0.49-2.05,P=1.0),使用TNF抑制剂和/或糖皮质激素者感染率未升高;707例接种与未接种IBD患者严格匹配后疾病加重风险分别为29%与26%(P=0.3),无显著差异。
要点
- IBD患者接种两剂BNT162b2后COVID-19发生率与非IBD对照相当(两组均为0.3%)。
- 使用TNF抑制剂和/或糖皮质激素的IBD患者感染发生率未升高。
- 接种与未接种IBD患者疾病加重风险分别为29%与26%(P=0.3),无显著差异。
核心结论
- IBD患者接种COVID-19疫苗的有效性与非IBD对照相当,且不受TNF抑制剂或糖皮质激素治疗影响。
- 接种与未接种疫苗的IBD患者疾病加重率无差异。
研究设计与样本
- 基于epi-Israeli IBD Research Nucleus验证队列的人群研究,纳入以色列4个健康维护组织中2个的IBD患者,覆盖35%人口。
- 2020年12月至2021年6月接受两剂辉瑞-BioNTech BNT162b2疫苗的IBD患者与非IBD对照个体匹配。
- 评估IBD结局时,接种与未接种IBD患者匹配,并按药物治疗分析应答。
主要发现
- 共12109例IBD患者接受两剂疫苗,其中4946例与非IBD对照匹配(平均年龄51±16岁;中位随访22周,四分位距4-24)。
- 两组各15例(0.3%)接种后发生COVID-19(比值比1;95%CI 0.49-2.05;P=1.0)。
- 使用TNF抑制剂和/或糖皮质激素的患者感染发生率未升高。
- 707例接种IBD患者与未接种IBD患者严格匹配(中位随访14周,四分位距2.3-20.4),疾病加重风险接种组29% vs 未接种组26%(P=0.3)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Studies have shown decreased response to coronavirus disease 2019 (COVID-19) vaccinations in some populations. In addition, it is possible that vaccine-triggered immune activation could trigger immune dysregulation and thus exacerbate inflammatory bowel diseases (IBD). In this population-based study we used the epi-Israeli IBD Research Nucleus validated cohort to explore the effectiveness of COVID-19 vaccination in IBD and to assess its effect on disease outcomes. METHODS: We included all IBD patients insured in 2 of the 4 Israeli health maintenance organizations, covering 35% of the population. Patients receiving 2 Pfizer-BioNTech BNT162b2 vaccine doses between December 2020 and June 2021 were individually matched to non-IBD controls. To assess IBD outcomes, we matched vaccinated to unvaccinated IBD patients, and response was analyzed per medical treatment. RESULTS: In total, 12,109 IBD patients received 2 vaccine doses, of whom 4946 were matched to non-IBD controls (mean age, 51 ± 16 years; median follow-up, 22 weeks; interquartile range, 4-24). Fifteen patients in each group (0.3%) developed COVID-19 after vaccination (odds ratio, 1; 95% confidence interval, 0.49-2.05; P = 1.0). Patients on tumor necrosis factor (TNF) inhibitors and/or corticosteroids did not have a higher incidence of infection. To explore IBD outcomes, 707 vaccinated IBD patients were compared with unvaccinated IBD patients by stringent matching (median follow-up, 14 weeks; interquartile range, 2.3-20.4). The risk of exacerbation was 29% in the vaccinated patients compared with 26% in unvaccinated patients (P = .3). CONCLUSIONS: COVID-19 vaccine effectiveness in IBD patients is comparable with that in non-IBD controls and is not influenced by treatment with TNF inhibitors or corticosteroids. The IBD exacerbation rate did not differ between vaccinated and unvaccinated patients.
引用
- Lev-Tzion R, Focht G, Lujan R, et al. COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation. Clin Gastroenterol Hepatol. 2021. PMID: 34954338. doi:10.1016/j.cgh.2021.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。